Survival benefit of mantle cell lymphoma patients enrolled in clinical trials; a joint study from the LYSA group and French cancer registries.

Date publication

octobre 2017

Journal

Journal of cancer research and clinical oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BERTAUT Aurélie , Pr MAYNADIE Marc , Dr WORONOFF Anne-Sophie

Tous les auteurs :
Augustin A, Le Gouill S, Gressin R, Bertaut A, Monnereau A, Woronoff AS, Trétarre B, Delafosse P, Troussard X, Moreau A, Hermine O, Maynadié M

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/29022078

Résumé

Mantle cell lymphoma (MCL) is a rare non-Hodgkin's lymphoma entity with a poor prognosis. Therapeutic advances have improved the survival of patients enrolled in clinical trials; however, their impact on patients outside clinical trials remains unclear. In this work, we compared patient outcome inside and outside clinical trials.

Mots clés

Clinical trial inclusion, Mantle cell lymphoma, Non-Hodgkin’s lymphoma, Population-based registry, Prognostic factors

Référence

J. Cancer Res. Clin. Oncol.. 2017 Oct;: